# Koninklijke Philips N.V. share price today (Koninklijke Philips N.V., PHG)

> Koninklijke Philips N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PHG · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/phg

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $28.46 (+4.2% in a year)
- P/E: 26.0×, against its own history
- Revenue (Jun 2026): EUR 4.4 B (+0.5% on a year ago)
- Profit (Jun 2026): EUR 386 M (+60.2% on a year ago)
- Operating margin: 14.0% (+4.8 points on a year ago)
- ROE: 8%, FY25
- ROIC: 6.6%, against a 7.6% cost of capital: −1.0 points
- Profit that came in as cash: 147%, last 2 years

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Koninklijke Philips N.V. share price today? Koninklijke Philips N.V.'s share price was $28.46 at the close on 3 November 2026. It has been stalling near its high for 1 week. That is 4.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $24 and $32, and at that close it sat 56% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 10 years the share price moved +22% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Koninklijke Philips N.V. pay? Koninklijke Philips N.V. declared EUR 0.85 per local share for Dec 2025. It reports in euros, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield. ## Which stock lists is Koninklijke Philips N.V. on? Koninklijke Philips N.V. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Koninklijke Philips N.V. profitable? Koninklijke Philips N.V. earned EUR 386 M of net profit in the Jun 2026 quarter, +60.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was EUR 896 M. Over 4 years profit has grown −27.9% a year on average. That is 8.9% of the quarter's revenue. The same quarter a year earlier earned EUR 241 M. 2 of the last 12 reported quarters were loss-making. Why profit moved: revenue changed +0.5% on a year earlier and the margin moved +4.8 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +55.4% and revenue −1.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## How much revenue does Koninklijke Philips N.V. make, and is it growing? Koninklijke Philips N.V. reported EUR 4.4 B of revenue in the Jun 2026 quarter, +0.5% on the same quarter a year earlier. Over 4 years it has grown 1.0% a year on average. The last full year, FY25, came in at EUR 17.8 B. The last four reported quarters add to EUR 17.7 B. Recent pace: the last four quarters grew −1.2% on average, against 1.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −1.1%, against −1.3% a year over the last 8 quarters (stabilising). This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## How much of its sales does Koninklijke Philips N.V. keep? Koninklijke Philips N.V.'s operating margin was 14.0% in the Jun 2026 quarter, 4.8 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −1.0% and 8.0%. The latest quarter is above every full year in that period. Across 5 years it has been between −1.0% and 8.0%, and FY25's 8.0% is the highest of them. Why the margin moved: operating margin changed +4.8 percentage points on the year while gross margin changed +2.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Koninklijke Philips N.V.'s profit turning into cash? Over the last 2 years, 147% of Koninklijke Philips N.V.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in EUR 1.2 B of operating cash against EUR 896 M of profit. After EUR 269 M of spending on assets, EUR 893 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## Where does Koninklijke Philips N.V.'s cash go? Koninklijke Philips N.V. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent EUR 931 M on assets over the last 3 years. Averaged over those years that is 1.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: EUR 931 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## What is Koninklijke Philips N.V.'s P/E ratio, and how does it compare with its own history? Koninklijke Philips N.V.'s P/E is 26.0×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Koninklijke Philips N.V. business getting better or worse? Koninklijke Philips N.V.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Koninklijke Philips N.V. earn on its capital? Koninklijke Philips N.V. earned a ROE of 8% in FY25. That is up from a low of −12% in FY22. Its return on capital used (ROIC) is 1.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 5.0% net margin and 0.66× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 5.0% net margin × 0.66× asset turnover × 2.45× leverage (assets divided by equity) ≈ 8.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 6.6% − 7.6% = −1.0 percentage points. The 7.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Koninklijke Philips N.V. have too much debt? Koninklijke Philips N.V. has total debt of EUR 7.5 B against shareholder equity of EUR 11.5 B as of Jun 2026, so its debt is 0.65× its equity. Year by year, that ratio went from 0.48 in FY21 to 0.74 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in euros, not US dollars, so the money charts are left out here. The figures in the text are in that currency (EUR); nothing is converted. ## What is the Koninklijke Philips N.V. shareholding pattern? We have no ownership or short-position figures for Koninklijke Philips N.V., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 2.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Koninklijke Philips N.V. from balance-sheet trouble? For Koninklijke Philips N.V., the Z-score is 2.02. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.02 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Koninklijke Philips N.V. rank in its industry? 52.3 out of 100, rank 11 of 30 in Medical Devices, with 71% of the evidence available. Koninklijke Philips N.V. scores 52.3 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 11. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.9 + 10.4 + 10 + 10 = 52.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Koninklijke Philips N.V. compared with? Koninklijke Philips N.V. ranks 11 of 30 Medical Devices companies on the 4-Factor Sector Score, with 52.3 out of 100. 1. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) DXCM · losing its lead · Most evidence points up · 81% evidence 74.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 15.5% · Profit 74.8% · Operating margin change 5.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 27.8% · Operating margin 24.3% · 76% evidence Valuation 13.6/20 · P/E 26× · PEG 0.66 · 65% evidence Relative strength 11.6/20 · Lead over its industry 2.6% · Lead over S&P 500 8.7% · 1 year 50.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28 + 20.9 + 13.6 + 11.6 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) GMED · basing · Evidence leans up · 81% evidence 63.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 19.8% · Profit 50.1% · Operating margin change 7.5 points · 83% evidence Capital efficiency 17.5/25 · ROCE 14.6% · Operating margin 24.8% · 76% evidence Valuation 14.9/20 · P/E 20× · PEG 0.4 · 65% evidence Relative strength 3.3/20 · Lead over its industry -15.4% · Lead over S&P 500 -10.3% · 1 year -5.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28 + 17.5 + 14.9 + 3.3 = 63.7 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -5.1%. 3. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) BSX · quiet · Evidence leans up · 81% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 13.5% · Profit 46.7% · Operating margin change 4.3 points · 83% evidence Capital efficiency 16.3/25 · ROCE 11.4% · Operating margin 22.9% · 76% evidence Valuation 15.6/20 · P/E 17.3× · PEG 0.37 · 65% evidence Relative strength 4.8/20 · Lead over its industry -38.8% · Lead over S&P 500 -35.7% · 1 year -56.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 16.3 + 15.6 + 4.8 = 61.7 · What this means: Earnings are strong; relative strength in its sector is -38.8% and the one-year return is -56.5%. 4. [Haemonetics Corporation](https://www.sectoralpha.in/us/stocks/hae) HAE · leader · Evidence leans up · 81% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0.3% · Profit -40.5% · Operating margin change 0 points · 83% evidence Capital efficiency 15.3/25 · ROCE 11.8% · Operating margin 17.9% · 76% evidence Valuation 13.3/20 · P/E 36.5× · PEG 0.49 · 65% evidence Relative strength 19.7/20 · Lead over its industry 36.9% · Lead over S&P 500 44.6% · 1 year 76% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.8 + 15.3 + 13.3 + 19.7 = 59.1 · What this means: Relative strength against the index is 44.6%, and revenue and profit growth are weak. 5. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) PODD · turning · Evidence leans up · 71% evidence 58.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 29.4% · Profit 58.6% · Operating margin change -2.5 points · 83% evidence Capital efficiency 18.9/25 · ROCE 21.3% · Operating margin 16.2% · 76% evidence Valuation 9.3/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 6.5/20 · Lead over its industry -31% · Lead over S&P 500 -27.5% · 1 year -51.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.8 + 18.9 + 9.3 + 6.5 = 58.5 · What this means: Earnings are strong; relative strength in its sector is -31% and the one-year return is -51.6%. 6. [Stryker Corporation](https://www.sectoralpha.in/us/stocks/syk) SYK · basing · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 8.5% · Profit 27.8% · Operating margin change 5 points · 83% evidence Capital efficiency 18.8/25 · ROCE 14.9% · Operating margin 27% · 76% evidence Valuation 11.0/20 · P/E 32.4× · PEG 1.16 · 65% evidence Relative strength 4.8/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.7% · 1 year -12.8% · 100% evidence · 1 of 12 weeks ahead Exact sum: 22.6 + 18.8 + 11 + 4.8 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) GKOS · leader · Evidence leans up · 64% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.2/35 · Revenue 41.8% · Profit n/a · Operating margin change 9.8 points · 62% evidence Capital efficiency 3.9/25 · ROCE -9.7% · Operating margin -8.5% · 76% evidence Valuation 11.2/20 · P/E -98.1× · PEG n/a · 15% evidence Relative strength 19.7/20 · Lead over its industry 53.6% · Lead over S&P 500 62.8% · 1 year 177.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.2 + 3.9 + 11.2 + 19.7 = 57 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Medtronic plc](https://www.sectoralpha.in/us/stocks/mdt) MDT · breaking out · Evidence leans up · 85% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 9.8% · Profit 12.3% · Operating margin change 0.6 points · 95% evidence Capital efficiency 14.3/25 · ROCE 9.4% · Operating margin 19.3% · 76% evidence Valuation 9.3/20 · P/E 20.9× · PEG 1.72 · 65% evidence Relative strength 12.8/20 · Lead over its industry -1.7% · Lead over S&P 500 3.9% · 1 year 7.2% · 100% evidence · 9 of 12 weeks ahead Exact sum: 19.1 + 14.3 + 9.3 + 12.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) STE · basing · Evidence leans up · 81% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 8.3% · Profit 24.7% · Operating margin change 1.4 points · 83% evidence Capital efficiency 15.4/25 · ROCE 12.2% · Operating margin 19.2% · 76% evidence Valuation 12.5/20 · P/E 25.5× · PEG 1 · 65% evidence Relative strength 7.3/20 · Lead over its industry -10.1% · Lead over S&P 500 -4.9% · 1 year -12.3% · 100% evidence · 3 of 12 weeks ahead Exact sum: 19.7 + 15.4 + 12.5 + 7.3 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) EW · turning · Evidence leans up · 81% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 14.6% · Profit -75.8% · Operating margin change 1.7 points · 83% evidence Capital efficiency 18.6/25 · ROCE 14.8% · Operating margin 29.8% · 76% evidence Valuation 3.9/20 · P/E 51.8× · PEG 5.03 · 65% evidence Relative strength 13.2/20 · Lead over its industry 0.1% · Lead over S&P 500 6.2% · 1 year 14.2% · 100% evidence · 2 of 12 weeks ahead Exact sum: 18.1 + 18.6 + 3.9 + 13.2 = 53.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. Koninklijke Philips N.V. this page PHG · turning · Evidence leans up · 71% evidence 52.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.9/35 · Revenue -1.1% · Profit 100% · Operating margin change 4.8 points · 83% evidence Capital efficiency 10.4/25 · ROCE 9% · Operating margin 14% · 76% evidence Valuation 10.0/20 · P/E 20.7× · PEG n/a · 15% evidence Relative strength 10.0/20 · Lead over its industry -6.6% · Lead over S&P 500 -1% · 1 year 1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 21.9 + 10.4 + 10 + 10 = 52.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 12. [CONMED Corporation](https://www.sectoralpha.in/us/stocks/cnmd) CNMD · quiet · Evidence leans up · 81% evidence 52.2 out of 100 Growth Capital Valuation Relative
13. [Integer Holdings Corporation](https://www.sectoralpha.in/us/stocks/itgr) ITGR · losing its lead · Too little evidence to rank firmly · 56% evidence 50.8 out of 100 Growth Capital Valuation Relative
14. [iRhythm Holdings, Inc.](https://www.sectoralpha.in/us/stocks/irtc) IRTC · turning · Evidence leans down · 64% evidence 49.4 out of 100 Growth Capital Valuation Relative
15. [Butterfly Network, Inc.](https://www.sectoralpha.in/us/stocks/bfly) BFLY · quiet · Evidence leans down · 61% evidence 48.9 out of 100 Growth Capital Valuation Relative
16. [UFP Technologies, Inc.](https://www.sectoralpha.in/us/stocks/ufpt) UFPT · losing its lead · Evidence leans down · 81% evidence 48.3 out of 100 Growth Capital Valuation Relative
17. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) SNN · turning · Too little evidence to rank firmly · 51% evidence 48.1 out of 100 Growth Capital Valuation Relative
18. [LivaNova PLC](https://www.sectoralpha.in/us/stocks/livn) LIVN · turning · Evidence leans down · 64% evidence 47.6 out of 100 Growth Capital Valuation Relative
19. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) GEHC · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
20. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) ZBH · turning · Evidence leans down · 81% evidence 45.9 out of 100 Growth Capital Valuation Relative
21. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) BRKR · turning · Evidence leans down · 71% evidence 44.9 out of 100 Growth Capital Valuation Relative
22. [Neogen Corporation](https://www.sectoralpha.in/us/stocks/neog) NEOG · turning · Evidence leans down · 67% evidence 44.8 out of 100 Growth Capital Valuation Relative
23. [Bio-Rad Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/bio) BIO · leader · Evidence leans down · 71% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Axogen, Inc.](https://www.sectoralpha.in/us/stocks/axgn) AXGN · turning · Evidence leans down · 64% evidence 42.1 out of 100 Growth Capital Valuation Relative
25. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) ESTA · basing · Evidence leans down · 61% evidence 40.7 out of 100 Growth Capital Valuation Relative
26. [Inspire Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/insp) INSP · breaking out · Evidence leans down · 74% evidence 39.4 out of 100 Growth Capital Valuation Relative
27. [NovoCure Limited](https://www.sectoralpha.in/us/stocks/nvcr) NVCR · quiet · Evidence leans down · 61% evidence 37.8 out of 100 Growth Capital Valuation Relative
28. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) PEN · turning · Evidence leans down · 81% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [TransMedics Group, Inc.](https://www.sectoralpha.in/us/stocks/tmdx) TMDX · quiet · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
30. [Abbott Laboratories](https://www.sectoralpha.in/us/stocks/abt) ABT · turning · Most evidence points down · 85% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Devices](https://www.sectoralpha.in/us/sectors/medical-devices), all 30 compared on one page. ## Which companies are close to Koninklijke Philips N.V. in size? Koninklijke Philips N.V. is the 8th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Edwards Lifesciences Corporation, GE HealthCare Technologies Inc. and DexCom, Inc. Just below it: STERIS plc, Zimmer Biomet Holdings, Inc. and Glaukos Corporation. ### Medical Devices companies close in size

1. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) $54.9 billion
2. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) $36.5 billion
3. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) $30.9 billion
4. Koninklijke Philips N.V. $28.1 billion
5. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) $22.6 billion
6. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) $18.5 billion
7. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) $13.8 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [FirstEnergy Corp.](https://www.sectoralpha.in/us/stocks/fe) $27.6 billion · Utilities - Regulated Electric
2. [VICI Properties Inc.](https://www.sectoralpha.in/us/stocks/vici) $27.5 billion · REIT - Diversified
3. Koninklijke Philips N.V. $27.5 billion
4. [Jabil Inc.](https://www.sectoralpha.in/us/stocks/jbl) $27.4 billion · Electronic Components
5. [ON Semiconductor Corporation](https://www.sectoralpha.in/us/stocks/on) $27.3 billion · Semiconductors

## What else do people ask about Koninklijke Philips N.V.? ### What were Koninklijke Philips N.V.'s latest quarterly results? Koninklijke Philips N.V. reported revenue of EUR 4.4 B and net profit of EUR 386 M for the Jun 2026 quarter. Revenue rose 0.5% and profit rose 60.2% compared with a year earlier. The operating margin was 14.0%, 4.8 percentage points higher than a year earlier (as of 3 November 2026). ### What is Koninklijke Philips N.V.'s market cap? Koninklijke Philips N.V.'s market capitalisation is $28.1 B at a stock price of $28.46. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Koninklijke Philips N.V. performing? Koninklijke Philips N.V.'s share price has been stalling near its high for 1 weeks. In its latest quarter, revenue rose 0.5% and profit rose 60.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 3 November 2026). ### Will Koninklijke Philips N.V.'s stock price go up? This page does not forecast Koninklijke Philips N.V.'s stock price. What it shows instead: the stock price is $28.46, and it has been stalling near its high for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Koninklijke Philips N.V. have too much debt? Koninklijke Philips N.V. has a moderate amount of debt: its debt is 0.70× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Koninklijke Philips N.V. in its business cycle? Koninklijke Philips N.V.'s FY25 operating margin was 8.0%, against a 5-year range of −1.0% to 8.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 14.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Koninklijke Philips N.V. story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Koninklijke Philips N.V. a stock worth studying right now? What the numbers show: Koninklijke Philips N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.